Skip to content

US · CYTK · BIOTECHNOLOGY

Cytokinetics, Incorporated (CYTK) intrinsic value and stock valuation

$50.78as of 2026-11-21 · Mkt cap 9.81B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Cytokinetics, Incorporated DCF and intrinsic value

InvestorsCraft values CYTK with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from CYTK’s statements →

Cytokinetics, Incorporated Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology South San Francisco, CA 94080 cytokinetics.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$88M+9.5% 5y CAGRd
20112025
Net income
-$-784.96M
20112025
Free cash flow
-$-534.82M
20112025
Total equity
-$-659.62M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$88M$18.5M$7.53M$94.6M$70.4M
Operating income-$-612.26M-$-536.25M-$-496.2M-$-324.2M-$-186.31M
Net income-$-784.96M-$-589.53M-$-526.24M-$-388.95M-$-215.31M
EPSd-$-6.54M-$-5.26M-$-5.45M-$-4.33M-$-2.8M
Operating cash flow-$-510.01M-$-395.89M-$-414.33M-$-299.52M-$-142.52M
Capital expenditure-$-24.81M-$-3.91M-$-1.42M-$-11.34M-$-48.87M
Free cash flow-$-534.82M-$-399.8M-$-415.75M-$-310.85M-$-191.39M
Total assets$1.42B$1.4B$824.3M$1.01B$841.3M
Total debt$1.28B$788.7M$755.8M$750.3M$269.9M
Net debt$1.16B$693.8M$642.8M$684.7M$157.3M
Total equity-$-659.62M-$-135.37M-$-386.32M-$-107.9M$243.9M
Cash and short-term investments$882.2M$1.08B$614.8M$782.6M$471.6M
Income statement
20252024202320222021
Revenue$88M$18.5M$7.53M$94.6M$70.4M
Cost of revenue$10.1M$339.4M$330.1M$240.8M$159.9M
Gross profit$77.9M-$-320.93M-$-322.59M-$-146.22M-$-89.51M
Research and development expenses$405.9M$339.4M$330.1M$240.8M$159.9M
Selling, general and administrative expenses$284.3M$215.3M$173.6M$178M$96.8M
Other expenses$0.00-$-339.41M-$-330.12M-$-240.81M-$-159.94M
Operating expenses$690.2M$215.3M$173.6M$178M$96.8M
Cost and expenses$700.3M$554.7M$503.7M$418.8M$256.7M
Interest income$48.4M$51.5M$27.6M$11.3M$330K
Interest expense$103.9M$86.5M$57.7M$51.2M$29.3M
Depreciation and amortization$9.69M$9.53M$11.9M$8.4M$9.64M
Ebitda-$-775.27M-$-493.48M-$-456.68M-$-329.4M-$-176.34M
Operating income-$-612.26M-$-536.25M-$-496.2M-$-324.2M-$-186.31M
Total other income/expenses, net-$-172.7M-$-53.28M-$-30.04M-$-64.75M-$-29M
Income before tax-$-784.96M-$-589.53M-$-526.24M-$-388.95M-$-215.31M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-784.96M-$-589.53M-$-526.24M-$-388.95M-$-215.31M
Weighted average shares outstanding$120M$112M$96.5M$89.8M$76.9M
Weighted average diluted shares outstanding$120.1M$112M$96.5M$89.8M$76.9M
Balance sheet
20252024202320222021
Cash and short-term investments$882.2M$1.08B$614.8M$782.6M$471.6M
Net receivables$17.8M$16.7M$1.28M$150K$51.8M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$917M$1.11B$628.1M$795.2M$535.7M
Property, plant and equipment, net$155.2M$141M$147.7M$163.2M$146.4M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$335.1M$145.1M$40.5M$46.7M$152.1M
Total non-current assets$507.6M$293.7M$196.3M$219.6M$305.7M
Total assets$1.42B$1.4B$824.3M$1.01B$841.3M
Accounts payable$22.3M$20.4M$21.5M$25.6M$21.1M
Short-term debt$60.3M$30.5M$28M$13.8M$14.9M
Deferred revenue$1.61M$52.4M$0.00$0.00$0.00
Total current liabilities$202.5M$179.7M$102.7M$84.6M$71.9M
Long-term debt$1.22B$758.2M$727.8M$736.5M$255.1M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$87M
Total non-current liabilities$1.88B$1.36B$1.11B$1.04B$525.6M
Capital lease obligations$127.1M$131.6M$138.3M$139.7M$127.1M
Total liabilities$2.08B$1.54B$1.21B$1.12B$597.5M
Common stock$120K$120K$100K$90K$80K
Retained earnings-$-3.49B-$-2.7B-$-2.11B-$-1.59B-$-1.21B
Accumulated other comprehensive income (loss)$630K$2.4M-$-10K-$-3.59M-$-870K
Total equity-$-659.62M-$-135.37M-$-386.32M-$-107.9M$243.9M
Total investments$1.09B$1.13B$542.3M$763.7M$511M
Total debt$1.28B$788.7M$755.8M$750.3M$269.9M
Net debt$1.16B$693.8M$642.8M$684.7M$157.3M
Cash flow statement
20252024202320222021
Net income-$-784.96M-$-589.53M-$-526.24M-$-388.95M-$-215.31M
Depreciation and amortization$10.1M$9.53M$11.9M$5.81M$2.28M
Stock-based compensation$112.3M$97.8M$72.1M$47.9M$26.8M
Change in working capital-$-35.63M$35.7M$3.09M-$-24.7M$8.46M
Accounts receivable-$-1.11M-$-15.37M-$-1.14M$56.7M-$-47.4M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$2.66M-$-4.48M-$-3.48M$4.52M$1.05M
Net cash provided by operating activities-$-510.01M-$-395.89M-$-414.33M-$-299.52M-$-142.52M
Investments in property, plant and equipment-$-24.81M-$-3.91M-$-1.42M-$-11.34M-$-48.87M
Acquisitions, net$0.00$0.00$0.00$250.8M$98.9M
Net cash used for investing activities$16.7M-$-553.1M$239.3M-$-262.13M-$-147.78M
Common stock issued$36M$706.8M$164.2M$17.5M$312.1M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$524.5M$930.6M$221.3M$516.2M$320M
Net change in cash$30.4M-$-18.17M$46.2M-$-45.48M$29.7M
Cash at end of period$125.6M$95.2M$113.4M$67.2M$112.7M
Operating cash flow-$-510.01M-$-395.89M-$-414.33M-$-299.52M-$-142.52M
Capital expenditure-$-24.81M-$-3.91M-$-1.42M-$-11.34M-$-48.87M
Free cash flow-$-534.82M-$-399.8M-$-415.75M-$-310.85M-$-191.39M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Cytokinetics, Incorporated

        Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

        CEO
        Robert I. Blum
        Employees
        673
        Beta
        0.38

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Cytokinetics, Incorporated (CYTK)?

        Cytokinetics, Incorporated (CYTK) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is CYTK undervalued?

        CYTK trades at a price of $50.78 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.